The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence.
about
Therapeutic targeting of replicative immortalityA phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling.Genetically engineered mouse models of PI3K signaling in breast cancer.Targeting MYC in cancer therapy: RNA processing offers new opportunities.Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancersMYC, metabolism, cell growth, and tumorigenesis.Senescence at a glanceHistone deacetylase 1 plays a predominant pro-oncogenic role in Eμ-myc driven B cell lymphomaUsing body temperature, food and water consumption as biomarkers of disease progression in mice with Eμ-myc lymphoma.mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene.Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism.Molecular mechanisms of natural killer cell activation in response to cellular stress.Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer.Targeting RNA polymerase I to treat MYC-driven cancer.MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.mTORC signaling in hematopoiesis.AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells.Double-Hit Large B Cell Lymphoma.The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples.The human T-cell leukemia virus type-1 p30II protein activates p53 and induces the TIGAR and suppresses oncogene-induced oxidative stress during viral carcinogenesis.Enhanced antitumor activity of 3-bromopyruvate in combination with rapamycin in vivo and in vitro.Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphomaTherapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92
P2860
Q27027457-555B8085-74A4-4C59-8CFB-841E66DBE161Q27320446-491F3578-4AF6-48D8-960A-2CC8C5D88D2DQ34039568-57D48C02-D266-44D8-A8BE-BCA51457777AQ34332175-4E2226C3-1BCA-4C75-AF83-B864ED415917Q36762189-947896B9-6547-4D97-A426-F74C94BCEF86Q37031640-C0F6DF91-DD50-4C5C-A0AD-6488D5D11EBAQ37040243-57F50DCF-B9A5-45B8-860F-5A449A228FB3Q37168870-00FE5CDA-6DDF-440C-9666-73D970F105E7Q37439209-D9036910-86D1-4EF7-A71B-CD98DCC950F4Q37594415-93BD8E15-1F2F-4467-91D0-FC37BF31D204Q37605004-1D9F842C-0A22-4EF1-B816-FE4F201A0296Q37690225-B2AFE2C8-7017-4DEF-9375-21269D5415EFQ37706550-5957EF80-AD6A-4941-871B-856697377432Q38098383-89663454-FE44-4C10-BE84-27BADCF4BE39Q38125169-0D179D07-FA83-4D1C-A501-802437CE04D7Q38194418-B7ECE739-DF45-4DDB-A513-B3EEAEA049B3Q38233772-C345F0B6-0ACA-4A51-9D5A-90EB8A998366Q38704683-58FE06BF-4536-4258-BF42-A989360B1BD4Q39208340-2B6486E7-1EF5-4423-BA5B-00C6D72D4A19Q40510800-E1D2DA18-75E7-4084-BF9D-BF05A4458831Q45304558-6E0A64BB-1643-4B8E-8C38-A4A661C0EFD7Q48319540-1DD218DD-6E97-4F81-8F2C-421B3A66224DQ49806891-E97736C1-2F17-449C-85B0-6B9F9018545AQ51012303-A4EBC658-58F1-4660-BDFF-94414E0FC9CDQ58708387-66B78EB0-A997-490A-A0EE-26A25EFC1F7AQ58761702-D19A5D97-2963-41F5-9DD7-319C569DB9BA
P2860
The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The mTORC1 inhibitor everolimu ...... g oncogene-induced senescence.
@ast
The mTORC1 inhibitor everolimu ...... g oncogene-induced senescence.
@en
type
label
The mTORC1 inhibitor everolimu ...... g oncogene-induced senescence.
@ast
The mTORC1 inhibitor everolimu ...... g oncogene-induced senescence.
@en
prefLabel
The mTORC1 inhibitor everolimu ...... g oncogene-induced senescence.
@ast
The mTORC1 inhibitor everolimu ...... g oncogene-induced senescence.
@en
P2093
P2860
P50
P1433
P1476
The mTORC1 inhibitor everolimu ...... g oncogene-induced senescence.
@en
P2093
Christopher J Chan
Grant A McArthur
Katherine M Hannan
Kathryn M Kinross
Kelly Waldeck
Kym L Stanley
Meaghan Wall
Megan J Bywater
Megan V Astle
Michael Bots
P2860
P356
10.1158/2159-8290.CD-12-0404
P577
2012-12-14T00:00:00Z